Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 3:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 22,018 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Relapsed/Refractory Primary Central Nervous System Lymphoma
Interventions: Rituximab, Temozolomide, Tirabrutinib; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 26
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 19 more

Conditions: Kidney Stones, Renal Stones, Stones, Kidney, Urolithiasis
Interventions: Standard Ureteroscopy (URS), Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System; Device
Lead sponsor: Calyxo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Birmingham, Alabama • Gainesville, Florida • New York, New York + 3 more

Conditions: Niemann-Pick Type C Disease
Interventions: Nizubaglustat, Placebo; Drug
Lead sponsor: Azafaros B.V.; Industry
Eligibility: 4 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more

Conditions: Overweight or Obesity
Interventions: None - Observational study; Other
Lead sponsor: American Heart Association; Other
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2060
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions: KPL-387, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 33
States / cities: Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more

Conditions: Spontaneous Breathing Trial in ICU
Interventions: Automatic tube compensation (ATC), Pressure Support Ventilation (PSV); Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: Carboplatin, Cisplatin, Nab-paclitaxel, Paclitaxel, Pemetrexed, Ramucirumab, Rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more

Conditions: Obesity
Interventions: Placebo, Vibegron; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 45 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Epilepsy
Interventions: FDG-PET/fMRI/EEG imaging; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
Interventions: PAS-004 Capsule, PAS-004 Tablets; Drug
Lead sponsor: Pasithea Therapeutics Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Postural Tachycardia Syndrome
Interventions: Normal saline, Ropivacaine, Sham injection of saline, Stellate ganglion block; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Stanford, California

Conditions: Invasive Mold Infections
Interventions: Fosmanogepix IV infusion, Fosmanogepix oral tablet, Standard of care antifungal therapy; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 15 more

Conditions: Corneal Epithelial Disorders, Persistent Corneal Epithelial Defect
Interventions: Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Population Health
Interventions: Nikeland VR non-food marketing experience, Wendyverse VR food marketing experience; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 24 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Triple Negative Breast Cancer
Interventions: bulumtatug fuvedotin; Drug
Lead sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Duarte, California • La Jolla, California • Aurora, Colorado + 4 more

Conditions: Fabry Disease
Interventions: ERT, migalastat HCl; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 5 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Claseprubart, Placebo; Drug
Lead sponsor: Dianthus Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more

Conditions: Dermatomyositis
Interventions: Ruxolitinib Topical Cream; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Cancer
Interventions: Bevacizumab, Trastuzumab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 33
States / cities: Burbank, California • La Jolla, California • Palo Alto, California + 26 more

Conditions: Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer
Interventions: ALE.P02, Pembrolizumab; Drug
Lead sponsor: Alentis Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Scottsdale, Arizona • Fullerton, California • Los Angeles, California + 5 more

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: osimertinib, stereotactic radiosurgery (SRS); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: PTSD - Post Traumatic Stress Disorder
Interventions: Cognitive Processing Therapy, Prolonged Exposure, Skills Training for Affective and Interpersonal Regulation; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Radiation-Induced Xerostomia and Hyposalivation
Interventions: Placebo, RXRG001; Biological
Lead sponsor: RiboX Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Mesothelioma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Sarcoma
Interventions: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 16
States / cities: Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more

Search by objective public record fields.

IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

Healthy Living BEYOND Weight Study

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

Automatic Tube Compensation vs. Pressure Support Ventilation During Spontaneous Breathing Trials in Adults

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Vibegron for ENergy Thinking and Resilience in Aging

PET/MRI/EEG Imaging Study in Epilepsy

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

The Young Adults' Experiences With Virtual Reality (YAES VR) Study

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

A Study of Patients With Fabry Disease (US Specific)

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Evaluating Evidenced Based Options for PTSD Treatment

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

Lead-212 PSV359 Therapy for Patients With Solid Tumors